MX369156B - Formulaciones de adenovirus mejoradas. - Google Patents

Formulaciones de adenovirus mejoradas.

Info

Publication number
MX369156B
MX369156B MX2016003414A MX2016003414A MX369156B MX 369156 B MX369156 B MX 369156B MX 2016003414 A MX2016003414 A MX 2016003414A MX 2016003414 A MX2016003414 A MX 2016003414A MX 369156 B MX369156 B MX 369156B
Authority
MX
Mexico
Prior art keywords
formulations
adenovirus formulations
improved adenovirus
improved
adenoviruses
Prior art date
Application number
MX2016003414A
Other languages
English (en)
Other versions
MX2016003414A (es
Inventor
Adriaansen Janik
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49212683&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX369156(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of MX2016003414A publication Critical patent/MX2016003414A/es
Publication of MX369156B publication Critical patent/MX369156B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses

Abstract

La presente invención se refiere a formulaciones farmacéuticas de adenovirus, en particular formulaciones farmacéuticas líquidas que comprenden adenovirus.
MX2016003414A 2013-09-19 2014-09-16 Formulaciones de adenovirus mejoradas. MX369156B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13185200 2013-09-19
PCT/EP2014/069654 WO2015040002A1 (en) 2013-09-19 2014-09-16 Improved adenovirus formulations

Publications (2)

Publication Number Publication Date
MX2016003414A MX2016003414A (es) 2016-06-30
MX369156B true MX369156B (es) 2019-10-30

Family

ID=49212683

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016003414A MX369156B (es) 2013-09-19 2014-09-16 Formulaciones de adenovirus mejoradas.

Country Status (32)

Country Link
US (3) US9974737B2 (es)
EP (1) EP3046536B1 (es)
JP (1) JP6013654B2 (es)
KR (1) KR102258348B1 (es)
CN (2) CN105530917B (es)
AP (1) AP2016009154A0 (es)
AU (1) AU2014323230B2 (es)
BR (1) BR112016005761B1 (es)
CA (1) CA2923352C (es)
CL (1) CL2016000621A1 (es)
CY (1) CY1122796T1 (es)
DK (1) DK3046536T3 (es)
EA (1) EA036046B1 (es)
ES (1) ES2711115T3 (es)
HR (1) HRP20182159T1 (es)
HU (1) HUE041791T2 (es)
IL (1) IL244572A (es)
LT (1) LT3046536T (es)
ME (1) ME03324B (es)
MX (1) MX369156B (es)
MY (1) MY181190A (es)
NZ (1) NZ717156A (es)
PE (1) PE20160527A1 (es)
PH (1) PH12016500316A1 (es)
PL (1) PL3046536T3 (es)
PT (1) PT3046536T (es)
RS (1) RS58393B1 (es)
SG (1) SG11201601181SA (es)
SI (1) SI3046536T1 (es)
TR (1) TR201900274T4 (es)
WO (1) WO2015040002A1 (es)
ZA (1) ZA201601919B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2988780T3 (en) 2013-04-25 2019-04-08 Janssen Vaccines & Prevention Bv STABILIZED SOLVEN RSV-F PREFUSION POLYPTIDES
EP3561062A1 (en) 2013-09-13 2019-10-30 California Institute of Technology Selective recovery
PL3046536T3 (pl) 2013-09-19 2019-06-28 Janssen Vaccines & Prevention B.V. Ulepszone formulacje adenowirusów
BR112017028449A2 (pt) 2015-07-07 2018-09-04 Janssen Vaccines & Prevention Bv polipeptídeos rsv f pré-fusão solúveis estabilizados
BR112017027448A2 (pt) 2015-07-07 2018-09-04 Janssen Vaccines & Prevention Bv vacina contra rsv
EP3359132B1 (en) * 2015-10-06 2023-08-16 Janssen Vaccines & Prevention B.V. Methods for preventing plastic-induced degradation of biologicals
CA3007495C (en) 2015-12-11 2023-04-11 California Institute Of Technology Targeting peptides for directing adeno-associated viruses (aavs)
CA3018139A1 (en) 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
SG11201807913XA (en) 2016-04-05 2018-10-30 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f proteins
SG11201810078PA (en) 2016-05-30 2018-12-28 Janssen Vaccines & Prevention Bv Stabilized pre-fusion rsv f proteins
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
US11229692B2 (en) 2017-05-17 2022-01-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
EP3681533A1 (en) 2017-09-15 2020-07-22 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against rsv
SG11202103102WA (en) 2018-09-26 2021-04-29 California Inst Of Techn Adeno-associated virus compositions for targeted gene therapy
US20220096375A1 (en) * 2019-01-09 2022-03-31 Ziccum Ab Stabilized non-enveloped virus compositions
CN117999353A (zh) * 2021-07-08 2024-05-07 拜奥卡德联合股份公司 无包膜病毒的药物组合物
WO2023240196A1 (en) * 2022-06-08 2023-12-14 Gritstone Bio, Inc. Compositions and methods of use thereof
EP4338727A1 (en) 2022-09-14 2024-03-20 Roquette Freres Adenovirus formulations
WO2024079657A1 (en) * 2022-10-11 2024-04-18 Meiragtx Uk Ii Limited Formulations for aav gene therapy

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
EP1548118A2 (en) 1994-06-10 2005-06-29 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
AU731767B2 (en) 1995-06-15 2001-04-05 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
EP1133316B1 (en) * 1998-11-16 2009-01-21 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) * 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US7456009B2 (en) * 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
EP1263461A4 (en) * 2000-03-07 2009-08-12 Merck & Co Inc ADENOVIRUS FORMULATIONS
CA2469491A1 (en) * 2001-12-12 2003-06-19 Kerrie Setiawan Composition for viral preservation
AU2002366809A1 (en) * 2001-12-20 2003-07-09 Schering-Plough Corporation Syn3 compositions and methods
US20030180936A1 (en) * 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
MXPA04008891A (es) 2002-04-25 2004-11-26 Crucell Holland Bv Medios y metodos para la produccion de vectores de adenovirus.
SG156535A1 (en) 2002-12-17 2009-11-26 Crucell Holland Bv Recombinant viral-based malaria vaccines
CN100429220C (zh) 2003-06-04 2008-10-29 坎基股份有限公司 用于干扰素治疗的方法和组合物
CN1859926B (zh) * 2003-06-30 2011-02-09 坎基股份有限公司 腺病毒的聚合物包裹
US20070148765A1 (en) * 2003-11-19 2007-06-28 Evans Robert K Preservative-containing virus formulations
EP1726640B1 (en) 2004-03-04 2016-01-13 Sumitomo Dainippon Pharma Co., Ltd. Rat embryonic stem cell
CN101090974B (zh) 2004-11-16 2011-05-11 克鲁塞尔荷兰公司 包含重组病毒载体的多价疫苗
CN1883707A (zh) * 2006-05-19 2006-12-27 吉林大学 重组腺病毒的冻干制剂及其制备方法
GB0715723D0 (en) * 2007-08-11 2007-09-19 Ark Therapeutics Ltd Formulation
US20110059079A1 (en) * 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody Coformulations
GB201002419D0 (en) 2010-02-12 2010-03-31 Isis Innovation Stable live vaccine formulations
EA201391043A1 (ru) 2011-02-17 2014-03-31 Сентисс Фарма Прайвет Лимитед Способ и композиция для замедления сорбции консервантов пластиками
PL3046536T3 (pl) 2013-09-19 2019-06-28 Janssen Vaccines & Prevention B.V. Ulepszone formulacje adenowirusów
CN104027815A (zh) 2014-06-12 2014-09-10 中国农业科学院兰州畜牧与兽药研究所 一种丹参酮包合液及其制备方法和应用
EP3359132B1 (en) 2015-10-06 2023-08-16 Janssen Vaccines & Prevention B.V. Methods for preventing plastic-induced degradation of biologicals

Also Published As

Publication number Publication date
AU2014323230A1 (en) 2016-03-17
CL2016000621A1 (es) 2016-11-25
HRP20182159T1 (hr) 2019-02-22
KR20160055180A (ko) 2016-05-17
CN111514314A (zh) 2020-08-11
EA036046B1 (ru) 2020-09-18
IL244572A0 (en) 2016-04-21
US20160199426A1 (en) 2016-07-14
PH12016500316B1 (en) 2016-05-02
BR112016005761A2 (es) 2017-08-01
PL3046536T3 (pl) 2019-06-28
ME03324B (me) 2019-10-20
AP2016009154A0 (en) 2016-04-30
IL244572A (en) 2017-02-28
PT3046536T (pt) 2019-02-25
MX2016003414A (es) 2016-06-30
HUE041791T2 (hu) 2019-05-28
CA2923352C (en) 2022-05-03
SI3046536T1 (sl) 2019-05-31
ES2711115T3 (es) 2019-04-30
CA2923352A1 (en) 2015-03-26
EP3046536B1 (en) 2018-11-28
US20190240146A1 (en) 2019-08-08
PH12016500316A1 (en) 2016-05-02
CY1122796T1 (el) 2021-05-05
ZA201601919B (en) 2017-06-28
LT3046536T (lt) 2019-03-12
EA201690613A1 (ru) 2016-08-31
US9974737B2 (en) 2018-05-22
US10272032B2 (en) 2019-04-30
WO2015040002A1 (en) 2015-03-26
CN105530917B (zh) 2020-06-05
CN105530917A (zh) 2016-04-27
JP2016530220A (ja) 2016-09-29
SG11201601181SA (en) 2016-04-28
BR112016005761B1 (pt) 2022-09-20
MY181190A (en) 2020-12-21
NZ717156A (en) 2022-04-29
JP6013654B2 (ja) 2016-10-25
DK3046536T3 (en) 2019-03-11
US11484494B2 (en) 2022-11-01
AU2014323230B2 (en) 2017-05-25
PE20160527A1 (es) 2016-05-20
TR201900274T4 (tr) 2019-02-21
EP3046536A1 (en) 2016-07-27
US20180235871A1 (en) 2018-08-23
KR102258348B1 (ko) 2021-05-31
RS58393B1 (sr) 2019-04-30

Similar Documents

Publication Publication Date Title
PH12016500316A1 (en) Improved adenovirus formulations
WO2013173789A3 (en) Antisense oligonucleotide compositions
IL252512B (en) Stable liquid formulations of the vaccinia virus
JO3755B1 (ar) تركيبات تستوستيرون
EP2978423A4 (en) STABLE NANO COMPOSITION WITH DOXORUBICIN, PROCESS FOR THE PREPARATION THEREOF, THE USE THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREWITH
SI3261676T1 (sl) Formulacije tekočega levotiroksina
IL241823B (en) Preparations containing novyi .c and their uses for the treatment of cancerous tumors
EP3319643A4 (en) HBED-BISPHOSPHONATES, CONJUGATES OF RADIOACTIVE METAL THEREOF, AND THEIR USE AS THERANOSTIC AGENTS
ES2651188T8 (es) Composición líquida fotopolimerizable
EP3369380A4 (en) COLLIMATOR FOR USE IN A SCANNING SYSTEM
EP2978428A4 (en) STABLE NANO COMPOSITION WITH EPIRUBICIN, PROCESS FOR THE PRODUCTION THEREOF, THE USE THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREWITH
PL3360547T3 (pl) Bakteriobójcza kompozycja farmaceutyczna zawierająca ibuprofen
MY165088A (en) Pharmaceutical compositions comprising alisporivir
MX2015012905A (es) Formulaciones de factor viii recombinantes.
IL250913A0 (en) Platinum (iv) complexes, preparations containing them and their uses
EP3132038A4 (en) Adenoviral targeting, compositions and methods therefor
MX345263B (es) Formulación de pexiganan estable.
EP3048886A4 (en) 3, 4-bis-benzylsulfonylbutanenitrile and its pharmaceutical use
FR3003757B1 (fr) Compositions cosmetiques triphasiques comprenant des nacres
赵潇雨 Choose
UA90689U (uk) Комплексний протипаразитарний препарат "лактоверм"
TH1501000860A (th) สิ่งเตรียมทางเภสัชกรรมชนิดของแข็งที่มีลีไวไธโรซีน
TH1501004545A (th) องค์ประกอบทางเภสัชกรรมที่มีเด็กซ์คีโตโพรเฟนและทรามาดอล
TH1401007610A (th) องค์ประกอบที่ประกอบด้วยสารออกฤทธิ์ทางชีวภาพ

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.

FG Grant or registration